Toggle navigation
Home
Search
Services
Blog
Contact
About
Phase II Clinical Trial of Dfmo and Nsaidin Colon - Workstatement 45-261975019
University of California Irvine
Search grants from University of California Irvine
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Publications
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Anatomical connections subserving the default mode network
Neuronal Circuits Controlling Behavior: Genetic Analysis in Zebrafish
Modulation of parasympathetic neurons by PACAP peptides
Migration & Layer Formation in Developing Visual Cortex
Training in Allergy and Immunology
Recently added grants:
The Role of the Microbiome and Notch Signaling in Esophageal Adenocarcinoma
Leveraging platelet contraction cytometry for immune thrombocytopenia
Prescription opioids, cognitive decline, and Alzheimers disease in older adults
Machine learning with immunogenetics for the prediction of hematopoietic cell transplant outcomes
Interplay between AMPK and Hippo Signaling Regulates Ocular Antiviral Response to Zika virus infection
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CA075019-004
Application #
6688678
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2002
Total Cost
Indirect Cost
Institution
Name
University of California Irvine
Department
Type
DUNS #
City
State
Country
Zip Code
Related projects
NIH 2003
N01 CA
Phase II Clinical Trial of Dfmo and Nsaidin Colon - Workstatement 45-261975019
/ University of California Irvine
NIH 2002
N01 CA
Phase II Clinical Trial of Dfmo and Nsaidin Colon - Workstatement 45-261975019
/ University of California Irvine
Publications
Beeram, M; Tan, Q-T N; Tekmal, R R et al.
(2007)
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.
Ann Oncol 18:1323-8
Comments
Be the first to comment on this grant